Q4 concall updates
Fy 24 guidance 10% growth with 19% ebidta
With europe at 20% usa at 5% Row and india at 10%.
Europe 4 filings which will boost fy 25 and beyond.respiratory doung well. Entering italy.
Usa more than 10 launches planned for fy24, munroe remediation mostly over. Some batches to be produced in q2 and commercial operations from h2.
India respiratory, cardio and derma doing well competitive pressure on diabetes. Focus reduced on institutional due to lower margins. Remediation on in baddi and goa, likely to be operational by h2. Mr strength at 4800.
Debt increase due to increase in working capital due to larger debtor period in europe and row, forex impact. Fy26 net debt zero target stands. On account of higher cash flows, gls stake sale etc.
Ryaltris doing better than expected expect to move to 45 mn usd in fy 24 from 23 mn sale in fy 23.
Ichnos q4 bump in cost due to one time payoff to people laid off. Going forward ichnos cost to be 60 mn usd pa.1342 poc likely by q3 now. One outlicensind deal from ichnos/glenmark in fy24.
| Subscribe To Our Free Newsletter |
